SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
- PMID: 34951565
- PMCID: PMC8774049
- DOI: 10.1080/22221751.2021.2023329
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells
Abstract
The novel SARS-CoV-2 Omicron variant (B.1.1.529), first found in early November 2021, has sparked considerable global concern and it has >50 mutations, many of which are known to affect transmissibility or cause immune escape. In this study, we sought to investigate the virological characteristics of the Omicron variant and compared it with the Delta variant which has dominated the world since mid-2021. Omicron variant replicated more slowly than the Delta variant in transmembrane serine protease 2 (TMPRSS2)-overexpressing VeroE6 (VeroE6/TMPRSS2) cells. Notably, the Delta variant replicated well in Calu3 cell line which has robust TMPRSS2 expression, while the Omicron variant replicated poorly in this cell line. Competition assay showed that Delta variant outcompeted Omicron variant in VeroE6/TMPRSS2 and Calu3 cells. To confirm the difference in entry pathway between the Omicron and Delta variants, we assessed the antiviral effect of bafilomycin A1, chloroquine (inhibiting endocytic pathway), and camostat (inhibiting TMPRSS2 pathway). Camostat potently inhibited the Delta variant but not the Omicron variant, while bafilomycin A1 and chloroquine could inhibit both Omicron and Delta variants. Moreover, the Omicron variant also showed weaker cell-cell fusion activity when compared with Delta variant in VeroE6/TMPRSS2 cells. Collectively, our results suggest that Omicron variant infection is not enhanced by TMPRSS2 but is largely mediated via the endocytic pathway. The difference in entry pathway between Omicron and Delta variants may have an implication on the clinical manifestations or disease severity.
Keywords: Delta variant; Omicron variant; SARS-CoV-2; TMPRSS2; viral replication.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures




Similar articles
-
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.Nature. 2022 Mar;603(7902):706-714. doi: 10.1038/s41586-022-04474-x. Epub 2022 Feb 1. Nature. 2022. PMID: 35104837 Free PMC article.
-
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.EBioMedicine. 2021 Mar;65:103255. doi: 10.1016/j.ebiom.2021.103255. Epub 2021 Mar 4. EBioMedicine. 2021. PMID: 33676899 Free PMC article.
-
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.J Virol. 2021 Oct 13;95(21):e0097521. doi: 10.1128/JVI.00975-21. Epub 2021 Aug 18. J Virol. 2021. PMID: 34406858 Free PMC article.
-
Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.J Genet. 2021;100(1):12. doi: 10.1007/s12041-021-01262-w. J Genet. 2021. PMID: 33707363 Free PMC article. Review.
-
Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.Mol Biol Rep. 2021 May;48(5):4667-4675. doi: 10.1007/s11033-021-06390-1. Epub 2021 May 22. Mol Biol Rep. 2021. PMID: 34023987 Free PMC article. Review.
Cited by
-
Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Children and Utility of Rapid Antigen Testing as an Indicator of Culturable Virus.Clin Infect Dis. 2023 Feb 8;76(3):e491-e494. doi: 10.1093/cid/ciac693. Clin Infect Dis. 2023. PMID: 36029095 Free PMC article.
-
Introduction, Spread and Impact of the SARS-CoV-2 Omicron Variants BA.1 and BA.2 in Cyprus.Microorganisms. 2022 Aug 23;10(9):1688. doi: 10.3390/microorganisms10091688. Microorganisms. 2022. PMID: 36144290 Free PMC article.
-
Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.Antiviral Res. 2022 Dec;208:105445. doi: 10.1016/j.antiviral.2022.105445. Epub 2022 Oct 17. Antiviral Res. 2022. PMID: 36265805 Free PMC article.
-
Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture.Commun Biol. 2022 Sep 14;5(1):958. doi: 10.1038/s42003-022-03841-8. Commun Biol. 2022. PMID: 36104427 Free PMC article.
-
Comparing the survival of adult inpatients with COVID-19 during the wild-type, Delta, and Omicron emergence.Public Health. 2022 Dec;213:124-126. doi: 10.1016/j.puhe.2022.10.014. Epub 2022 Oct 20. Public Health. 2022. PMID: 36410117 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous